

# Plexus Vaccine Incorporated

[View the current Plexus Vaccine Incorporated Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/8406-Plexus+Vaccine+Incorporated.html)

(<http://www.bioportfolio.com/bi corporate/8406-Plexus+Vaccine+Incorporated.html>)

## Contact Details:

**11770 Bernardo Plaza Court, Suite 370-B  
San Diego  
CA  
92128  
United States of America**

Tel: 858 385 9084  
Fax: 858 385 9086  
Email: [info@plexvax.com](mailto:info@plexvax.com)

Plexus employs powerful proprietary tools of computational protein structural biology combined with genomic bioinformatics analysis and the principles of rational drug design to create vaccines that induce specific mechanistic interventions in critical protein functions. For the first time, epitope-specific vaccines that generate neutralizing antibodies can be designed and synthesized from deduction and mimicry of the 3D structural features of epitopes, applying sophisticated methods of structure-based drug design.

The work is exploiting broadly protective epitopes revealed from our comparative structural analysis of vast numbers of genetic variants (polymorphisms) of pathogens. The Company applies proprietary advanced bioinformatics analysis against entire genomes of pathogens and their host species to find a new generation of safe and effective vaccines, with the mission of rapidly delivering robust protection from serious disease through its enabling technology and novel vaccine products for human and veterinary markets.

## Press Releases on Plexus Vaccine Incorporated:

|  |                     |   |   |
|--|---------------------|---|---|
| <a href="#">H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics</a>     | 20th November, 2009 | Quest Diagnostics Incorporated              | <i>-- Rates of positive test results for the pandemic have declined in recent weeks in most regions, with the exception of the Northeast, where rates have more than doubled during</i>                       |
| <a href="#">Case Studies Offer Inside Look at Effective Ways to Address Global Health Challenges</a> | 20th November, 2009 | Alliance for Case Studies for Global Health | <i>Publication to Serve as Guide to Understanding, Building Productive Partnerships WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Meaningful and lasting progress in addressing global health challenges</i> |

|  |                     |                                |  |
|--|---------------------|--------------------------------|--|
| <a href="#">New Hair Data Validate Sharp Downward Trend in Cocaine and Methamphetamine Positivity in General U.S. Workforce, According to Quest Diagnostics Drug Testing Index(TM)</a> | 20th November, 2009 | Quest Diagnostics Incorporated | MADISON, N.J., Nov. 20 /PRNewswire-FirstCall/ -- New data released today by Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of employment-related drug testing services,   |
| <a href="#">Spherix Announces the Closing of \$6.3 Million Registered Direct Offering</a>  | 19th November, 2009 | Spherix Incorporated           | BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting -- Robert J. Vander Zanden, Ph.D., former Vice President, R&D, Kraft Foods International In addition, Grant Thornton LLP was ratified as the Company's independent accountants |
| <a href="#">Spherix Announces Results of Annual Shareholders Meeting</a>   | 19th November, 2009 | Spherix Incorporated           |  |

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical

practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

